EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape

Mariya Gromova iD, Annegret Vaggelas, Gabriele Dallmann, Diane Seimetz

Biomarker Insights · 2020-01 · 15 · 117727192097465

DOI: 10.1177/1177271920974652 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomarker Insights, online erschienen am 08.12.2020. Verfasst von Mariya Gromova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biopharma Excellence GmbH, Munich, Germany. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarkers are widely used at every stage of drug discovery and development. Utilisation of biomarkers has a potential to make drug discovery, development and approval processes more efficient. An overview of the current global regulatory landscape is presented in this article with particular emphasis on the validation and qualification of biomarkers, as well as legal framework for companion diagnostics. Furthermore, this article shows how the number of approved drugs with at least 1 biomarker used during development (biomarker acceptance) is affected by the recent advances in the biomarker regulations. More than half of analysed approvals were supported by biomarker data and there has been a slight increase in acceptance of biomarkers in recent years, even though the growth is not continuous. For certain pharmacotherapeutic groups, approvals with biomarkers are more common than without. Examples include immunosuppressants, immunostimulants, drugs used in diabetes, antithrombotic drugs, antineoplastic agents and antivirals. As a conclusion, potential benefits, challenges and opportunities of using biomarkers in drug discovery and development in the current regulatory landscape are summarised and discussed.

Schlagwörter

Stichwörter der Autor:innen

BiomarkerEMAFDAcompanion diagnosticsdrug approvaldrug developmentqualificationregulatory landscape

Autor:innen und Institutionen

  • Biopharma Excellence GmbH, Munich, Germany.

ORCID-Profile: Mariya Gromova

Zitieren

APA

Gromova, M., Vaggelas, A., Dallmann, G., & Seimetz, D. (2020). Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. Biomarker Insights, 15, 117727192097465. https://doi.org/10.1177/1177271920974652

Vancouver

Gromova M, Vaggelas A, Dallmann G, Seimetz D. Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. Biomarker Insights. 2020;15:117727192097465. doi:10.1177/1177271920974652

BibTeX
@article{Gromova2020,
  author = {Gromova, Mariya and Vaggelas, Annegret and Dallmann, Gabriele and Seimetz, Diane},
  title = {Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape},
  journal = {Biomarker Insights},
  year = {2020},
  volume = {15},
  pages = {117727192097465},
  doi = {10.1177/1177271920974652}
}
Kostenlos starten →